Emerging therapies to lower lipoprotein(a) and the current clinical trials landscape: RNA-therapeutics and beyond
Journal of Clinical Lipidology · 2026-07
DOI: 10.1016/j.jacl.2026.06.025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Lipidology, 2026-07. Verfasst von Sawye Raygani und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California San Diego (UCSD), San Diego, United States. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Larry L. Hillblom Foundation, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of California San Diego (UCSD), San Diego, United States.
- Department of Medicine, Division of Cardiovascular Medicine, University of California San Diego (UCSD), San Diego, United States. Electronic address: mjwilkinson@health.ucsd.edu.
Förderung
- Larry L. Hillblom Foundation
- National Institutes of Health
Zitieren
APA
Raygani, S., & Wilkinson, M. J. (2026). Emerging therapies to lower lipoprotein(a) and the current clinical trials landscape: RNA-therapeutics and beyond. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.06.025
Vancouver
Raygani S, Wilkinson MJ. Emerging therapies to lower lipoprotein(a) and the current clinical trials landscape: RNA-therapeutics and beyond. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.06.025
BibTeX
@article{Raygani2026,
author = {Raygani, Sawye and Wilkinson, Michael J},
title = {Emerging therapies to lower lipoprotein(a) and the current clinical trials landscape: RNA-therapeutics and beyond},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2026.06.025}
}
EUVIMED